Abiomed Inc (Abiomed) develops innovative heart pump technologies to support patients with severe coronary artery disease and heart failure. Its lead products include the Impella family of heart pumps, which offer percutaneous catheter-based technology for temporary hemodynamic support. These pumps allow the heart to rest and recover by assisting with efficiently delivering blood and oxygen throughout the body.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Abiomed emphasizes clinical research while backing the development and validation of its Impella heart pumps. Abiomed has completed seven FDA studies and five post-market approval studies. It has sponsored or attempted eight randomized controlled trials (RCTs), including the PROTECT II RCT, to demonstrate the safety and efficacy of Impella heart pumps in cardiogenic shock. Currently, the company is conducting the STEMI DTU trial in partnership with the FDA, comparing delayed reperfusion with unloading to the standard immediate reperfusion approach. Abiomed is also sponsoring the PROTECT IV and RECOVER IV RCTs. PROTECT IV aims to validate best practices for high-risk PCI patients, while RECOVER IV will assess the benefit of Impella pre-PCI in AMI cardiogenic shock patients.